There are over ninety #myeloma treatments in development in the US alone. We can help you find, understand and connect to the ones that might be right for you. Get started by creating your free profile: buff.ly/3yFVQr0 #clinicaltrial #mmsm

This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple #myeloma patients. buff.ly/3wRi5df #clinicaltrial #mmsm

Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple #Myeloma. buff.ly/3Re7S1s #clinicaltrial #mmsm

Elranatamab is a bi-specific antibody used in the treatment of multiple #myeloma. It works by binding to both CD3 on T cells and BCMA expressed on malignant plasma cells. Learn more about this therapy and associated clinical trials: buff.ly/3Vq3Unv #clinicaltrial #mmsm

The mission of the NCI-designated Sidney Kimmel Cancer Center is to improve the lives of cancer patients and their families through innovation, compassion, and breakthrough discoveries. For more information, visit: buff.ly/3Ry5RgB #myeloma #clinicaltrial #mmsm

Did you know there are over a dozen clinical trials available for patients with Smoldering "Asymptomatic" #Myeloma? We can help you evaluate smoldering trials that may be right for you. buff.ly/4c3madt #clinicaltrial #mmsm

This Phase I study is designed to determine the safety and find the recommended Phase 2 dose of Belantamab Mafodotin in patients with high-risk smoldering multiple #myeloma. buff.ly/3KKpnmn #clinicaltrial #mmsm

Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple #Myeloma buff.ly/4b9tDqd #clinicaltrial #mmsm

Monoclonal Antibodies are treatments that use your immune system function to fight cancer. Antibodies are cloned and used to attack one specific type of protein found in cancer cells.To learn more visit: buff.ly/4eE2qig #myeloma #clinicaltrial #mmsm

The team at the Barbara Ann Karmanos Cancer Institute is entirely focused on treating hematologic malignancies and shares its expertise to create a customized treatment plan for each patient. Learn more: #myeloma #clinicaltrial #mmsm buff.ly/4eCoh9L

Let us do the heavy lifting for you. Add trials and treatment centers to your list of favorites in your profile and we'll send you alerts to keep you informed of any new updates that are made. Create your account today: buff.ly/3xHgqHk #myeloma #clinicaltrial #mmsm

A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple #Myeloma buff.ly/3zcw3XP #clinicaltrial #mmsm

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple #Myeloma Who Have Had an Autologous Stem Cell Transplant #clinicaltrial #mmsm buff.ly/45DKFeY

CC-220 is a immunomodulator being developed by Celgene Corporation. CD-220, also called iberdomide, binds the protein Cereblon which is one of the mechanisms of action for the immunomodulator drugs. Learn more: buff.ly/3LRdOKH #myeloma #clinicaltrial #mmsm

The Siteman Cancer Center is an international leader in cancer treatment, research, prevention, education and community outreach. It is the only cancer center in Missouri to hold the prestigious Comprehensive Cancer Center designation. buff.ly/4dwq12W

Visit myeloma.org/sparkcures to start searching today! Or get even more personalized options when you create an account on myeloma.org #ash24 #imfash24 SparkCures

Don't miss your chance to ask YOUR questions LIVE on Sat. 7/19 @ 10:15am PST! IMF CMO Joseph Mikhael, SparkCures founder Brian McMahon, & myeloma patient advocate Thomas Goode break down #myeloma clinical trials in this 30-min power session. RSVP: mmsm.link/3Tp7uxw #mmsm

Don't miss your chance to ask YOUR questions LIVE on Sat. 7/19 @ 10:15am PST! IMF CMO Joseph Mikhael, SparkCures founder Brian McMahon, & myeloma patient advocate Thomas Goode break down #myeloma clinical trials in this 30-min power session. RSVP: mmsm.link/3Tp7uxw #mmsm

Join IMF Chief Medical Officer Joseph Mikhael, SparkCures founder Brian McMahon, & myeloma patient advocate Thomas Goode for our Facebook LIVE Q&A on Saturday, July 19 at 10:15am PST! RSVP now so you don’t miss out: facebook.com/events/1196152… #AsktheIMF #mmsm

How do I join a clinical trial for relapsed myeloma? Dr. Joseph Mikhael, Chief Medical Officer of the IMF, answers in this new video. Find a clinical trial at myeloma.org/sparkcures Watch the full video with Dr. Joe at myeloma.org/node/11799 #AsktheIMF #mmsm SparkCures